Metastasen bei unbekanntem Primärtumor — CUP-Syndrom

  • G. Hübner
  • I. Wildfang
  • H.-J. Schmoll

Zusammenfassung

Der Begriff „Metastasen bei unbekanntem Pirmärtumor“ bezeichnet ein vielgestaltiges onkologisches Krankheitsbild, das sich durch eine Reihe gemeinsamer biologischer Charakteristika auszeichnet. Es sollte als eigenständiges Syndrom aufgefaßt werden, da es spezifische diagnostische und therapeutische Vorgehensweisen erfordert. Im folgenden wird es als CUP-Syndrom (Carzinom mit unbekanntem Primärtumor, Cancer of Unknown Primary) bezeichnet; dieser Ausdruck hat sich in der internationalen Literatur weitgehend durchgesetzt (Nissenblatt 1981; Pasterz et al. 1985).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abbruzzese JL, Lenzi R, Raber MN, Pathak S, Frost P (1993) The biology of unknown primary tumors. Semin Oncol 20: 238–243PubMedGoogle Scholar
  2. al-Idrissi HY (1990) Combined 5-fluorouracil, adriamycin and mitomycin C in the management of adenocarcinoma metastasizing to the liver from an unknown primary site. J Int Med Res 18: 425–429PubMedGoogle Scholar
  3. Altman E, Cadman E (1986) An analysis of 1539 patients with cancer of unknown primary site. Cancer 57: 120–124PubMedCrossRefGoogle Scholar
  4. Atkin NB (1986) Chromosone 1 aberrations in cancer. Cancer Genet Cytogenet 21: 279–285PubMedCrossRefGoogle Scholar
  5. Azar HA, Espinoza CG, Richman AV, Saba SR, Wang TY (1982) „Undifferentiated“ large cell malignancies: An ultrastructural and immunocytochemical study. Hum Pathol 13: 323–333Google Scholar
  6. Baron MG, de-la-Gandara I, Espinosa E, de-Paredes ML, Zamora P, Mondejar JL (1991) Bone metastases as the first manifestation of a tumour. Int Orthop 15: 373–376PubMedCrossRefGoogle Scholar
  7. Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA (1990) Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg 125: 210–214Google Scholar
  8. Bataini JP, Rodriguez J, Jaulerry C, Brugere J, Ghossein NA (1987) Treatment of metastatic neck nodes secondary to an occult epidermoid carcinoma of the head and neck. Laryngoscope 97: 1080–1084PubMedCrossRefGoogle Scholar
  9. Batsakis JG (1981) The pathology of head and neck tumors: the occult primary and metastases to the head and neck. Head Neck Surg 3: 409–423PubMedCrossRefGoogle Scholar
  10. Bell CW, Pathak S, Frost P (1989) Unknown primary tumors: establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumor progression. Cancer Res 49: 4311–4315PubMedGoogle Scholar
  11. Chan RC, Steinbok P (1982) Solitary cerebral metastasis: the effect of craniotomy on the quality and the duration of survival. Neurosurgery 11: 254–257PubMedCrossRefGoogle Scholar
  12. Chee CP (1990) Brain metastasis of unknown origin. Singapore Med J 31: 48–50PubMedGoogle Scholar
  13. Clark WC, Nicoll JA, Coakham H (1989) Monoclonal antibody immunopheno-typing of solitary cerebral metastases with unknown primary sites. Br J Neurosurg 3: 591–595PubMedCrossRefGoogle Scholar
  14. Coker DD, Casterline PF, Chambers RG, Jaques DA (1977) Metastases to lymph nodes of the head and neck from an unknown primary site. Am J Surg 134: 517–522PubMedCrossRefGoogle Scholar
  15. Coster JR, Foote RL, Olsen KD, Jack SM, Schaid DJ, DeSanto LW (1992) Cervical nodal metastasis of squamous cell carcinoma of unknown origin: indications for withholding radiation therapy. Int J Radiat Oncol Biol Phys 23: 743–749PubMedCrossRefGoogle Scholar
  16. de Braud F, Heilbrun LK, Ahmed K et al. (1989) Metastatic squamous cell carcinoma of an unknown primary localized to the neck. Advantages of an aggressive treatment. Cancer 64: 510–515Google Scholar
  17. De Wit R, Hoek FJ, Bakker PJM, Veenhof CHN (1991) The value of MCA, CA 153, CEA and CA-125 for discrimination between metastatic breast cancer and adenocarcinoma of other primary sites. J Intern Med 229: 463–466PubMedCrossRefGoogle Scholar
  18. Debevec M (1990) Management of patients with brain metastases of unknown origin. Neoplasma 37: 601–606PubMedGoogle Scholar
  19. Dickersin GR, Scully RE (1993) Role of electron microscopy in metastatic endometrial stromal tumors. Ultrastruct Pathol 17: 377–403PubMedCrossRefGoogle Scholar
  20. Didolkar MS, Fanous N, Elias EG, Moore RH (1977) Metastatic carcinomas from occult primary tumors. A study of 254 patients. Ann Surg 186: 625–630PubMedCrossRefGoogle Scholar
  21. Dorman AM, Chin D, Leader M (1992) Specificity of colon specific antigen and colon ovarian tumour antigen. J Clin Pathol 45: 932–933PubMedCrossRefGoogle Scholar
  22. Dvorak AM, Monahan RA (1982) Metastatic adenocarcinoma of unknown primary site: diagnostic electron microscopy to determine the site of tumor origin. Arch Pathol Lab Med 106: 21–24PubMedGoogle Scholar
  23. Eapen L, Vachet M, Catton G et al. (1988) Brain metastases with an unknown primary: a clinical perspective. J Neurooncol 6: 31–35PubMedCrossRefGoogle Scholar
  24. Eichhorn JH, Young RH, Scully RE (1993) Nonpulmonary small cell carcinomas of extragenital origin metastatic to the ovary. Cancer 71: 177–186PubMedCrossRefGoogle Scholar
  25. Fer MF, Abrams PG, Oldham RK et al. (1986) Poorly differentiated lung cancer. In: Fer MF, Greco FA, Oldham RK (eds) Poorly differentiated neoplasms and tumors of unknown origin. Grune & Stratton, Orlando, pp 271–292Google Scholar
  26. Fitzpatrick PJ, Kotalik JF (1974) Cervical metastases from an unknown primary tumor. Radiology 110: 659–663PubMedGoogle Scholar
  27. Gaber AO, Rice P, Eaton C, Pietrafitta JJ, Spatz E, Deckers PJ (1983) Metastatic malignant disease of unknown origin. Am J Surg 145: 493–497PubMedCrossRefGoogle Scholar
  28. Gamble AR, Bell JA, Ronan JE, Pearson D, Ellis IO (1993) Use of tumour marker immunoreactivitiy to identify primary site of metastatic cancer. BMJ 306: 295–298PubMedCrossRefGoogle Scholar
  29. Garrow GC, Greco FA, Hainsworth JD (1993) Poorly differentiated neuroendo- crine carcinoma of unknown primary tumor site. Semin Oncol 20: 287–291PubMedGoogle Scholar
  30. Gatter KC, Alcock C, Heryet A, Mason DY (1985) Clinical importance of analysing malignant tumours of uncertain origin with immunohistological techniques. Lancet 1: 1302–1305PubMedCrossRefGoogle Scholar
  31. Goerich J, Beyer-Enke SA, Mueller M, Gueckel F, Probst G, van Kaick G (1988) Die Wertigkeit der Computertomographie bei der Suche nach unbekanntem Primärtumor. Rofo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 149: 277–279CrossRefGoogle Scholar
  32. Goldberg RM, Smith FP, Ueno W, Ahlgren JD, Schein PS (1986) 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 4: 395–399Google Scholar
  33. Greco FA, Vaughn WK, Hainsworth JD (1986) Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med 104: 547–553PubMedCrossRefGoogle Scholar
  34. Hainsworth JD, Greco FA (1993) Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site. Semin Oncol 20: 279–286PubMedGoogle Scholar
  35. Hainsworth JD, Johnson DH, Greco FA (1992) Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 10: 912–922PubMedGoogle Scholar
  36. Hainsworth JD, Wright EP, Johnson DH, Davis BW, Greco FA (1991) Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining. J Clin Oncol 9: 1931–1938PubMedGoogle Scholar
  37. Hammar SP, Orenstein JM (1992) Metastatic neoplasms of unknown primary origin: an overview. Ultrastruct Pathol 16: 3–5PubMedCrossRefGoogle Scholar
  38. Heater K, MacMahon H, Vyborny CJ (1989) Occult and lung carcinoma presenting with dysphagia. The value of computed tomography. Clin Imaging 13: 122–126Google Scholar
  39. Heyderman E, Chapman DV, Richardson TC, Calvert I, Rosen SW (1985) Human chorionic gonadotropin and human placental lactogen in extragonadal tumors. An immunoperoxidase study of ten non-germ cell neoplasms. Cancer 56: 2674–2682Google Scholar
  40. Holmes FF, Fouts TL (1970) Metastatic cancer of unknown primary site. Cancer 26: 826–820CrossRefGoogle Scholar
  41. Hübner G, Tamme C, Wildfang I, Schöber C, Schmoll H-J (1990) Management of patients with carcinoma of unknown primary ( CUP-Syndrome ). J Cancer Res Clin Oncol [Suppl, part I]: 116–190Google Scholar
  42. Jesse RH, Perez CA, Fletcher GH (1973) Cervical lymph node metastasis: unknown primary cancer. Cancer 31: 854–857PubMedCrossRefGoogle Scholar
  43. Jonk A, Kroon BB, Rumke P, Mooi WJ, Hart AA, van-Dongen JA (1990) Lymph node metastasis from melanoma with an unknown primary site. Br J Surg 77: 665–668PubMedCrossRefGoogle Scholar
  44. Köhne-Wömpner CH, Schmoll J-J, Wilke H et al. (1994) Weekly high dose infusional 5-fluorouracil (FU) plus leucovorin vs. FU plus a-interferon in advanced colorectal cancer. Ann Oncol 5 [Suppl 8]: 0219Google Scholar
  45. Krüger R, de-Leon F, Maihoff J (1992) Der Wert der Immunhistochemie bei der histologischen Routinediagnostik von Metastasen mit unbekannten Primärtumor. Pathologe 13: 65–72PubMedGoogle Scholar
  46. Lamerz R (1989) Klinische Relevanz von Tumormarkern. Wien Klin Wochenschr 101: 464–472PubMedGoogle Scholar
  47. Le Chevalier T, Cvitkovic E, Caille P et al. (1988) Early metastic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 148: 2035–2039PubMedCrossRefGoogle Scholar
  48. Lefèbvre JL, Adenis L, Coche-Dequeant B, Depadt G, Buisset E (1986) Cervical adenopathies of unknown primary site. Radiographics 6: 314–317Google Scholar
  49. Lenzi R, Raber MN, Frost P, Schmidt S, Abbruzzese JL (1993) Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. Eur J Cancer 29A: 1634–1634CrossRefGoogle Scholar
  50. Lopez R, Holyoke ED, Moore RH, Karakousis CP (1982) Malignant melanoma with unknown primary site. J Surg Oncol 19: 151–154PubMedCrossRefGoogle Scholar
  51. Loy TS, Abshier J (1993) Immunostaining with HAM56 in the diagnosis of adenocarcinomas. Mod Pathol 6: 473–475PubMedGoogle Scholar
  52. Mackay B, Ordonez NG (1993) Pathological evaluation of neoplasms with unknown primary tumor site. Semin Oncol 20: 206–228PubMedGoogle Scholar
  53. Markman M (1982) Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at The Johns Hopkins Hospital from 1965–1979. Med Pediatr Oncol 10: 569–574Google Scholar
  54. Maulard C, Housset M, Brunel Pet al. (1992) Postoperative radiation therapy for cervical lymph node metastases from an occult squamous cell carcinoma. Laryngoscope 102: 884–890PubMedCrossRefGoogle Scholar
  55. McKeen E, Smith F, Haidak D et al. (1980) Fluorouracil (F), adriamycin (A) and mitomycin (M), FAM, for adenocarcinoma of unknown origin. Proc ASCO 21: 358Google Scholar
  56. Merchut MP (1989) Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med 149: 1076–1080PubMedCrossRefGoogle Scholar
  57. Moertel CG, Reitemeier RJ, Schutt AJ, Hahn RG (1972) Treatment of the patient with adenocarcinoma of unknown origin. Cancer 30: 1469–1472PubMedCrossRefGoogle Scholar
  58. Nesbit RA, Tattersall MH, Fox RM, Woods RL (1981) Presentation of unknown primary cancer with metastatic liver disease–management and natural history. Aust N Z J Med 11: 16–19PubMedCrossRefGoogle Scholar
  59. Neumann G (1988) Bösartige Neubildungen mit sekundärem, nicht näher oder nicht bezeichnetem Sitz–ihre Bedeutung für die Todesursachenstatistik. Öff Gesundheitswes 50: 13–19Google Scholar
  60. Nissenblatt MJ (1981) The CUP syndrome (carcinoma unknown primary). Cancer Treat Rev 8: 211–224PubMedCrossRefGoogle Scholar
  61. Nole F, Colleoni M, Buzzoni R, Bajetta E (1993) Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary. Tumori 79: 116–118PubMedGoogle Scholar
  62. Nystrom JS, Weiner J; Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM (1977) Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 4: 53–58PubMedGoogle Scholar
  63. Nystrom JS, Weiner JM, Wolf RM, Bateman JR, Viola MV (1979) Identifying the primary site in metastatic cancer of unknown origin: inadequacy of roentgenographic procedures. JAMA 241: 381–383PubMedCrossRefGoogle Scholar
  64. Panza N, Lombardi G, De Rosa M, Pacilio G, Lapenta L, Salvatore M (1987) High serum thyreoglobulin levels. Diagnostic indicator in patients with metastases from unknown primary sites. Cancer 60: 2233–2236Google Scholar
  65. Pasterz R, Savaraj N, Burgess M, Legha S, Benjamin R, Schwarz B (1985) Analysis of prognostic factors in patients with metastatic carcinoma of unknown primary ( MCUP ). Proc ASCO 4: 151Google Scholar
  66. Patchell RA, Tibbs PA, Walsh JE et al. (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322: 494–500PubMedCrossRefGoogle Scholar
  67. Penn I (1991) Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 110: 726–734PubMedGoogle Scholar
  68. Peters GJ, Hoekman K, van Groeningen CJ et al. (1993) Potentiation of 5Fluororacil induced inhibition of thymidylate synthase in human colon tumors by leucovorin is dose dependent. Adv Exp Med Biol 338: 613–616PubMedCrossRefGoogle Scholar
  69. Reintgen DS, McCarty KS, Woodard B, Cox E, Seigler HF (1983) Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet 156: 335–340PubMedGoogle Scholar
  70. Remick SC, Ruckdeschel JC (1992) Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome. Med Pediatr Oncol 20: 89–99PubMedCrossRefGoogle Scholar
  71. Richardson RL (1986) Small cell carcinomas of extrapulmonary origin. In: Fer MF, Greco FA, Oldham RK (eds) Poorly differentiated neoplasms and tumors of unknown origin. Grune & Stratton, Orlando, pp 323–342Google Scholar
  72. Rougraff BT, Kneisl JS, Simon MA (1993) Skeletal metastases of unknown origin. A prospective study of a diagnostic strategy. J Bone Joint Surg Am 75: 1276–1281Google Scholar
  73. Ruddon RW (1986) Immunologic and biochemical markers in the diagnosis and management of poorly differentiated neoplasms and cancers of unknown primary. In: Fer MF, Greco FA,Oldham RK (eds) Poorly differentiated neoplasms and tumors of unknown origin. Grune & Stratton, Orlando, pp 75100Google Scholar
  74. Rudnick S, Tremont S, Staab E (1981) Evaluation and therapy of adenocarcinoma of unknown primary ( ACUP ). Proc ASCO 22: 379Google Scholar
  75. Santini H, Byers RM, Wolf PF (1985) Melanoma metastatic to cervical and parotic nodes from an unknown primary site. Am J Surg 150: 510–512PubMedCrossRefGoogle Scholar
  76. Schnürch HG (1992) Tumormetastasen in axillären Lymphknoten bei unbekanntem Primärtumor. Gynäkologe 25: 109–116PubMedGoogle Scholar
  77. Schultz-Coulon HJ, Peter HH (1984) Melanommetastasen im Halsbereich bei unbekanntem Primärtumor. Laryngol Rhinol Otol (Stuttg) 63: 17–20CrossRefGoogle Scholar
  78. Sheahan K, O’Keane JC, Abramowitz A et al. (1993) Metastatic adenocarcinoma of an unknown primary site. A comparison of the relative contributions of morphology, minimal essential clinical data and CEA immunostaining status. Am J Clin Pathol 99: 729–735Google Scholar
  79. Shih LY, Chen TH, Lo WH (1992) Skeletal metastasis from occult carcinoma. J Surg Oncol 51: 109–113PubMedCrossRefGoogle Scholar
  80. Shildt RA, Kennedy PS, Chen TT, Athens JW, O’Bryan RM, Balcerzak SP (1983) Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study. Cancer Treat Rep 67: 77–79PubMedGoogle Scholar
  81. Silverman C, Marks JE (1982) Metastatic cancer of unknown origin: epidermoid and undifferentiated carcinomas. Semin Oncol 9: 435–441PubMedGoogle Scholar
  82. Snee MP, Vyramuthu N (1985) Metastatic carcinoma from unknown primary site: the experience of a large oncology centre. Br J Radiol 58: 1091–1095PubMedCrossRefGoogle Scholar
  83. Stahl M, Wilke H, Preusser Petal. (1991) Etoposide, leukovorin and 5-fluorouracil ( ELF) in advanced gastric carcinoma - final results of a phase-II study in elderly patients or patients with cardiac risk. Onkology 14: 314–318Google Scholar
  84. Tan JL, Lo NN, Tan SK (1992) Surgical treatment of metastatic long bone disease. Singapore Med J 33: 355–358PubMedGoogle Scholar
  85. van der Gaast A, Verweij J, Prins E, Splinter TA (1990) Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas. Cancer 65: 422–424CrossRefGoogle Scholar
  86. van-Ooijen B, Bontenbal M, Henzen-Logmans SC, Koper PC (1993) Axillary nodal metastases from an occult primary consistent with breast carcinoma. Br J Surg 80: 1299–1300PubMedCrossRefGoogle Scholar
  87. Vanhoefer U, Wilke H, Weh H et al. (1994) Weekly high-dose 5-fluorouracil/folic acid is active in chemotherapeutically pretreated gastric cancer. Ann Oncol 5 [Suppl 8]: P 398Google Scholar
  88. Velez A, Walsh D, Karakousis CP (1991) Treatment of unknown primary melanoma. Cancer 68: 2579–2581PubMedCrossRefGoogle Scholar
  89. Verweij J, von de Gast A, von de Burg ME, Henzen-Logmans SC, Stoter G (1989) Phase 2 study of bleomycin, etoposide and cisplatin for patients with metastatic (adeno)carcinoma of unknown primary ( CUP ). Proc Natl Acad Sci USA 8: A1139Google Scholar
  90. Wax MK, Briant TD (1993) Surgery and postoperative radiotherapy in the management of extensive cancer of the cervical lymph nodes from an unknown primary. J Otolaryngol 22: 34–38PubMedGoogle Scholar
  91. Wilke H, Vanhoefer U, Fink U et al. (1994) Weekly high-dose fluorouracil/folinic acid plus biweekly Cisplatin or high-dose fluorouracil/folinic acid plus alternating cisplatin/epidoxorubicin for gastric cancer. Ann Oncol 5 [Suppl 81: P 397Google Scholar
  92. Zaren HA, Copeland EM 3d (1978) Inguinal node metastases. Cancer 41: 919–923PubMedCrossRefGoogle Scholar
  93. Zola P, Volpe T, Luparia E,Rumore A, Katsaros D, Sismondi P (1991) Localiza- tion and management of occult breast lesions. Eur J Gynaecol Oncol 12: 63–68Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • G. Hübner
  • I. Wildfang
  • H.-J. Schmoll

There are no affiliations available

Personalised recommendations